

Cachexia - Pipeline Insight, 2021

<https://marketpublishers.com/r/C691EFA840FEN.html>

Date: June 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: C691EFA840FEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Cachexia - Pipeline Insight, 2021," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cachexia Understanding

Cachexia: Overview

Cachexia is a "wasting" disorder that causes extreme weight loss and muscle wasting, and can include loss of body fat. It is a symptom of many chronic conditions, such as cancer, chronic renal failure, HIV, and multiple sclerosis. The main symptoms of the conditions are severe weight loss, including loss of fat and muscle mass, loss of appetite, anemia (low red blood cells), weakness and fatigue. Cachexia adversely affects the patients' ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. The goal of treatment for cachexia is to improve symptoms and quality of life. Current therapy for cachexia includes: appetite stimulants such as megestrol acetate drugs, medications that decrease inflammation, diet changes, nutritional supplements and exercise.

'Cachexia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

Cachexia Emerging Drugs Chapters

This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cachexia Emerging Drugs

GCWB 204: Green Cross Wellbeing

GCWB 204 (BST 204), a purified ginseng extract with reinforced ginsenosides Rh2 and Rg3. Green Cross Wellbeing is developing the drug as oral capsule in Phase II clinical studies for the treatment of cancer cachexia.

Ponsegromab: Pfizer

Ponsegromab (formerly PF-06946860) is subcutaneous, monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1). The drug is in

Phase I clinical developmental studies for the treatment of Cachexia.

Further product details are provided in the report..

Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cachexia

There are approx. 22+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. Phase II include, Green Cross Wellbeing.

Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

Cachexia Report Insights

Cachexia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cachexia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cachexia drugs?

How many Cachexia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers

and acquisitions, licensing activities related to the Cachexia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cachexia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Incyte Corporation

Green Cross Wellbeing

AEterna Zentaris

AVEO Oncology

AstraZeneca

Endevica Bio

Actimed Therapeutics

Creative Medical Technology Holdings

Ildong Pharmaceutical

Immuneering

Key Products

Ruxolitinib

GCWB 204

Macimorelin

AV 380

ART 2713

TCMCB-07

ACM-002

Research programme: amniotic stem cell therapies

ID 11917

Research programme: cancer therapeutics

Contents

Introduction

Executive Summary

Cachexia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cachexia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Cachexia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Cachexia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

GCWB 204: Green Cross Wellbeing

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)
Comparative Analysis
Ponsegromab: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
TCMCB-07: Endevida Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Cachexia Key Companies
Cachexia Key Products
Cachexia- Unmet Needs
Cachexia- Market Drivers and Barriers
Cachexia- Future Perspectives and Conclusion
Cachexia Analyst Views
Cachexia Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cachexia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Cachexia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Cachexia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C691EFA840FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C691EFA840FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970